Literature DB >> 33535235

Association of Genetic Polymorphisms in DC-SIGN, Toll-Like Receptor 3, and Tumor Necrosis Factor α Genes and the Lewis-Negative Phenotype With Chikungunya Infection and Disease in Nicaragua.

Filemón Bucardo1, Yaoska Reyes1, Marlen Morales1, Rafaela Briceño2, Fredman González1, Åke Lundkvist3, Lennart Svensson4,5, Johan Nordgren4.   

Abstract

BACKGROUND: Chikungunya infections range from subclinical infection to debilitating arthralgia and to chronic inflammatory rheumatism. Tumor necrosis factor (TNF) α, DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin), Toll-like receptor (TLR) 3, and blood groups have been directly or indirectly implicated in the susceptibility and pathogenesis of chikungunya.
METHODS: To test the hypothesis that polymorphisms in genes coding for these molecules determine clinical outcomes of chikungunya infection, a retrospective case-control study was performed in León, Nicaragua. The study included 132 case patients and 132 controls, matched for age, sex and neighborhood. Case patients had clinical symptoms of chikungunya, which was diagnosed by means of polymerase chain reaction. Controls were individuals not reporting abrupt presentation of clinical chikungunya-like symptoms. Polymorphisms were identified by TaqMan single-nucleotide polymorphism genotyping assays.
RESULTS: After adjustment for sociodemographic risk factors, chikungunya disease was associated with polymorphism in DC-SIGN and TLR3 genes (odds ratios, 5.2 and 3.3, respectively), and TNF-α with reduced persistent joint pain (0.24). Persistent joint pain was also associated with age, female sex and other comorbid conditions. Most interestingly, the Lewis-negative phenotype was strongly associated with both symptomatic chikungunya and immunoglobulin G seropositivity (odds ratios, 2.7, and 3.3, respectively).
CONCLUSION: This study identified polymorphisms in DC-SIGN, TLR3, and TNF-α genes as well as Lewis-negative phenotype as risk factors for chikungunya infection and disease progression.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Chikungunya; DC-SIGN; Lewis phenotype; Nicaragua; TLR3

Year:  2021        PMID: 33535235     DOI: 10.1093/infdis/jiaa364

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Association of tumor necrosis factor alpha -308 single nucleotide polymorphism with SARS CoV-2 infection in an Iraqi Kurdish population.

Authors:  Hussein N Ali; Sherko S Niranji; Sirwan M A Al-Jaf
Journal:  J Clin Lab Anal       Date:  2022-04-04       Impact factor: 3.124

Review 2.  A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development.

Authors:  Thaise Yasmine Vasconcelos de Lima Cavalcanti; Mylena Ribeiro Pereira; Sergio Oliveira de Paula; Rafael Freitas de Oliveira Franca
Journal:  Viruses       Date:  2022-05-05       Impact factor: 5.818

Review 3.  Chikungunya and Zika Viruses: Co-Circulation and the Interplay between Viral Proteins and Host Factors.

Authors:  Sineewanlaya Wichit; Nuttamonpat Gumpangseth; Rodolphe Hamel; Sakda Yainoy; Siwaret Arikit; Chuchard Punsawad; Dorothée Missé
Journal:  Pathogens       Date:  2021-04-09

4.  Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation.

Authors:  Natalia Redondo; Isabel Rodríguez-Goncer; Patricia Parra; Francisco López-Medrano; Esther González; Ana Hernández; Hernando Trujillo; Tamara Ruiz-Merlo; Rafael San Juan; María Dolores Folgueira; Amado Andrés; José María Aguado; Mario Fernández-Ruiz
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

Review 5.  Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention.

Authors:  Betsy Yang; Kuender D Yang
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.